Urinary Tract/Bladder Cancer Trials
PCYC-1128-CA
PCYC-1128-CA - A phase1b/2 study of Ibrutinib Combination Therapy in selected advanced gastrointestinal and genitourinary tumors (bladder, colon, gastric, renal)
-
What type of cancer? What stage?
- Advanced GU cancer (bladder and renal).
-
Who is eligible?
- Patients who have received prior chemotherapy.
-
How will I be treated?
- Patients will receive Ibrutinib with other chemotherapy or biologic therapy.
S1605
S1605 - Phase II trial of Atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.
-
What type of cancer? What stage?
- Early bladder cancer.
-
Who is eligible?
- Men with bladder cancer who have received BCG.
-
How will I be treated?
- Atezolizumab, an immunotherapy that acts on PDL1.
A031701
A031701 - A Phase II study of dose-dense Gemcitabine plus Cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA Damage Response (DDR) gene alterations.
-
What type of cancer? What stage?
- Bladder cancer.
-
Who is eligible?
- Patients must have muscle-invasive bladder cancer. They will be tested for a DDR mutation.
-
How will I be treated?
- This study looks at treating with chemotherapy for bladder preservation.
A031501
A031501 - Phase III randomized adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) versus observation.
-
What type of cancer? What stage?
- Urothelial cancers (bladder, ureter, or kidney).
-
Who is eligible?
- Patients who have had complete resection (TURBT that completely removed tumor is okay).
-
How will I be treated?
- The study looks at treating with Pembrolizumab, an anti-PD-1 immunotherapy.
SI602
SI602 - A Phase III randomized trial to evaluate the influence of BCG strain differences and T Cell priming with intradermal BCG intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer.
-
What type of cancer? What stage?
- Bladder cancer (no prior treatment).
-
Who is eligible?
- High-grade muscle-invasive bladder cancer.
-
How will I be treated?
- This study evaluates the effect of adding a vaccine to BCG therapy.
For physicians: more information about this specific trial at clinicaltrials.gov.
-
Let’s start with some good news: colorectal cancer diagnoses and mortality rates are on the decline. ...
Continue Reading -
When you own a house, you take care of it with regular maintenance. When you own a car, you take it to ...
Continue Reading